Veraxa Biotech Holding AG
VRXA
NASDAQ4.48
USD
-1.38
- -
CIK
0002079109
ISIN
CH1476899161
Return %
Stock
S&P500
1Y
-63.43
25.65
3Y
-63.43
70.81
5Y
-63.43
77.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Christoph Antz
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- TALACKER 35 Zurich ZH Switzerland 8001
- IPO Date
- Jun 9, 2026
- CIK
- 0002079109
- Website
- veraxa.com
- Similar Companies
- Business
- Veraxa Biotech Holding AG engages in the discovery, development, and advancement of next-generation antibody-based therapeutics for cancer, focusing on solid tumors and leveraging its BiTAC platform to enable conditionally activated, AND-gated strategies for increased therapeutic index; the company develops bispecific T cell engagers, antibody–drug conjugates, and related formats, with capabilities in click-chemistry conjugation, microfluidic screening, and internalization-optimized constructs across ADCs, BiTEs, and other novel formats. Veraxa operates through subsidiaries and ongoing transactions to consolidate related entities, expands its pipeline via BiTAC-enabled programs and radiopharmaceutical/conjugate platforms, and pursues partnerships for co-development and clinical progression. Headquartered in Zürich, Switzerland, Veraxa Biotech Holding AG conducts its activities through a global development footprint with clinical and research collaborations designed to advance oncology therapeutics toward the clinic and eventual commercialization. Founded in 2025, the group emerges from consolidating Veraxa Biotech AG and related entities, with a strategy to build a premier engine for discovery and development of antibody-based therapeutics and to leverage strategic alliances, potential mergers, and acquisitions to accelerate its growth trajectory in the biopharma landscape. The company's core products and services encompass therapeutic programs in ADCs, BiTEs, BiTAC-based constructs, targeted radiopharmaceuticals, and antibody conjugation technologies; development services include discovery, preclinical evaluation, analytical characterization, manufacturing process development, and translational research supporting clinical advancement; geographic operations span Europe and North America, with a focus on collaboration with biopharma partners and academic institutions to accelerate pipeline progression. Veraxa maintains a research-and-development orientation, emphasizes quality-by-design principles, and seeks to maximize patient benefit through precise tumor targeting while minimizing off-target effects. Recent corporate developments include a merger-related integration process under absorption merger terms leading to group reorganization and potential renaming to Veraxa Biotech AG, along with ongoing strategic partnerships, product pipeline expansion, and continued pursuit of co-development opportunities to broaden the commercial reach of its BiTAC-enabled therapeutics. The company is publicly tracked under ticker VRXA and maintains a strategic emphasis on solid-tumor indications, leveraging its platform across ADCs, bispecifics, and related modalities to address unmet medical needs in oncology.
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026